January 22, 2026 – Patient Worthy

ImmunityBio Reports Encouraging Evidence That ANKTIVA Enhances Immune Recovery in NSCLC When Paired With Checkpoint Inhibitors

Post author:Austin Newman
Post published:January 22, 2026
Post category:non-small cell lung cancer

As reported on Business Wire, ImmunityBio has released new clinical findings suggesting that its interleukin‑15 superagonist, ANKTIVA® (nogapendekin alfa inbakicept), may help restore immune function and improve survival outcomes in…

FDA Approves First Treatment for Stem Cell Transplant–Associated Thrombotic Microangiopathy

Post author:Austin Newman
Post published:January 22, 2026
Post category:Rare Disease

The U.S. Food and Drug Administration (FDA) has approved Yartemlea (narsoplimab‑wuug), marking the first authorized therapy for hematopoietic stem cell transplant‑associated thrombotic microangiopathy (TA‑TMA) in adults and children aged 2…

Immunotherapy Breakthrough Offers Teens with Hodgkin Lymphoma a Better Path Forward

Post author:Bree Clare
Post published:January 22, 2026
Post category:Hodgkin Lymphoma

Young cancer patients with advanced Hodgkin lymphoma now have access to a significantly more effective treatment option that dramatically reduces their need for radiation therapy and offers superior long-term survival…

ImmunityBio Reports Encouraging Evidence That ANKTIVA Enhances Immune Recovery in NSCLC When Paired With Checkpoint Inhibitors

FDA Approves First Treatment for Stem Cell Transplant–Associated Thrombotic Microangiopathy

Immunotherapy Breakthrough Offers Teens with Hodgkin Lymphoma a Better Path Forward

Let’s Work Together!

Keep Up to Date

Learn More